Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will deliver two presentations, including one oral, on its SENTI-202 clinical program, at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 6-9, 2025 in Orlando, Florida. Senti Bio will also host a live webcast to discuss the latest data during the annual meeting.

Read more at globenewswire.com